Ofatumumab (Kesimpta)
Ofatumumab (Kesimpta) is an injectable treatment for relapsing forms of MS to include clinically isolated syndrome, relapsing-remitting disease (RRMS), and active secondary progressive disease, in adults. Ofatumumab is a monoclonal antibody that binds to a docking site (CD20) on developing immune B cells. The binding results in depleting the B cells so that they cannot contribute to inflammation and nerve damage. Ofatumumab is similar to other MS therapies that bind to the CD20 receptor on B cells including rituximab and ocrelizumab. Ofatumumab is administered by subcutaneous injection monthly after an initial titration.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
